A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

BACKGROUND: Clostridium difficile infection (CDI) is a leading cause of diarrhoea in health care settings with symptoms ranging from mild and self-limiting to life threatening. SMT19969 is a novel, non-absorbable antibiotic currently under development for the treatment of CDI. Here we report the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, Richard, Robinson, Neil, Best, Emma, Echols, Roger, Tillotson, Glenn, Wilcox, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349307/
https://www.ncbi.nlm.nih.gov/pubmed/25880933
http://dx.doi.org/10.1186/s12879-015-0759-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349307/
https://www.ncbi.nlm.nih.gov/pubmed/25880933
http://dx.doi.org/10.1186/s12879-015-0759-5

Ejemplares similares